Background--Although generic medications are approved based on bioequivalence with brand-name medications, there remains substantial concern regarding their clinical effectiveness and safety. Lipitor â , available as generic atorvastatin, is one of the most commonly prescribed statins. Therefore, we compared the effectiveness of generic atorvastatin products and Lipitor â .
A torvastatin is a top-selling medication, with over 80 million prescriptions dispensed in the United States in 2014. In Canada, over 17 million prescriptions were filled for atorvastatin in 2012, totaling nearly $0.5 billion in sales. 1, 2 Generic atorvastatin was approved in Canada in June 2010, providing health care plans with an opportunity to save millions in medication costs. 3 Once available in generic form in Canada, Ontario's public prescription benefit program mandated universal substitution of any of the available generic atorvastatin products for all Lipitor â prescriptions.
After this mandatory generic policy was implemented, Ontario's public formulary atorvastatin costs dropped 74%, reducing atorvastatin expenditures from $316 million in 2009-2010 to $83 million in 2012-2013. 4 Whereas most clinicians and patients welcome decreased generic drug costs, it is essential that safety and effectiveness is not compromised. 5 Although generic drugs have identical active ingredients as brand-name drugs, they are not exact replicas because their inactive ingredients (excipients) differ. 6 Health Canada, like the US Food and Drug Administration (FDA), requires bioequivalence studies for generic drug approval. Bioequivalence studies typically enroll a small number of healthy volunteers (minimum, 12) who are usually given one dose of brand-name and generic drug, and focus on drug absorption, only needing to show that a similar amount of the generic drug was absorbed at a similar rate as the brand-name drug. [7] [8] [9] [10] Statin efficacy was originally demonstrated with brand-name statins versus placebo in large, secondary prevention trials with thousands of patients, reducing major coronary events by 27% to 44%, mortality by 13% to 30%, and coronary death by 18% to 42% in those with heart disease. [11] [12] [13] Given that generic medications are approved on the basis of bioequivalence with brand-name medications in healthy volunteers, rather than the target population with or at risk of cardiovascular disease, there remains a substantial uncertainty regarding their clinical effectiveness and safety, as well as the mandatory substitution policies that ensue following their approval. 11, 14, 15 The few studies that have directly compared brand and generic atorvastatin in patients have evaluated lipid values rather than clinical outcomes. [16] [17] [18] [19] [20] It is crucial to be able to provide strong clinical outcomes evidence regarding generic products in order to address concerns about their effectiveness and safety. The Ontario policy change affords a unique opportunity to compare clinical outcomes between generic atorvastatin preparations and Lipitor â in those with acute coronary syndromes (ACS), a population at the highest risk for adverse cardiac outcomes, at a time when Lipitor â was the most commonly prescribed statin, and during a period without other major competing health policy changes.
Methods

Design and Data Sources
We conducted a population-based observational study, creating a propensity-score-matched cohort by linking administrative health care databases for hospitalizations, prescription claims, and vital status using unique, encoded identifiers and analyzed at the Institute for Clinical Evaluative Sciences (Toronto, Ontario, Canada Figure 1 shows patient accrual). There were 9 generic atorvastatin products dispensed during our study (Apo-Atorvastatin, Co-Atorvastatin, Gd-Atorvastatin, Mylan-Atorvastatin, Novo-Atorvastatin, PMS-Atorvastatin, Ran-Atorvastatin, Ratio-Atorvastatin, and Sandoz-Atorvastatin).
Outcomes
The primary outcome was death or recurrent ACS hospitalization within 1 year. Secondary outcomes included hospitalization for heart failure, stroke, myopathy/rhabdomyolysis, renal insufficiency, and new-onset diabetes. ACS hospitalization and secondary outcomes were from discharge abstract data. Death was from the Ontario Registered Persons Database. Diabetes was ascertained using the Ontario Diabetes Mellitus Database (Table S1) . 21 Follow-up for ascertainment of outcomes began 7 days post-ACS discharge. Subjects who did not experience the event of interest were censored at the first occurrence of: switch from brand to generic (or vice versa) or after 1 year postindex date.
Statistical Analysis
To reduce potential confounding between treatment groups, we constructed a propensity-matched cohort as our primary analysis. The propensity score (the probability of receiving generic atorvastatin conditional on relevant baseline characteristics) was estimated using a multivariable logistic regression model. Variables in the propensity score model included those listed in Table 1 .
To ensure balance between groups on key variables that may be associated with outcomes of interest and perform subgroup analysis, greedy nearest neighbor caliper matching without replacement was used to match each generic atorvastatin patient with a Lipitor â patient using the logit of the propensity score, and on age (AE1 year), sex, diabetes, most responsible diagnosis at index admission (acute myocardial infarction [AMI] or angina), and statin daily dosage category (0-19, 20-39, and ≥40 mg). 22 A caliper width of 0.2 of the SD of the logit of the propensity score in the overall sample was used. 23 Generic atorvastatin patients without a suitable match were excluded from the cohort. To determine the degree of balance between the 2 groups in the matched cohort, we calculated standardized differences between groups for each of the measured baseline covariates, with a standardized difference of <0.1 indicative of good balance between groups for that covariate (Table 1 ).
In the propensity-score-matched cohort, Kaplan-Meier curves were estimated to compare survival between the treatment groups. Hazard ratios (HRs) and 95% CIs were calculated for the outcomes, including drug side effects, using Cox proportional hazard models with a robust sandwich-type variance estimator to account for the matched nature of the sample. 24, 25 Subgroup analyses, adjusted for covariates in the propensity score, were conducted for age (<75, ≥75 years), sex (male, female), past diabetes, Lipitor â /atorvastatin dose (<40 mg and ≥40 mg), and most responsible diagnosis (AMI or unstable angina). Pairs mismatched on age were excluded from the age subgroup analysis.
As a secondary analysis in the overall (nonpropensity score matched) cohort, we compared the primary outcome between generic atorvastatin preparations. We conducted a sensitivity analysis with the exposure of generic atorvastatin versus Lipitor â as a time-varying covariate, which allowed patients to switch between generic and brand atorvastatin without defining the grouping within 7 days of their ACS. To address concerns about the effect of secular trends in event rates, we reanalyzed our cohort limited to 1 year before and after the policy change. We also estimated mortality for the entire cohort at 7, 14, 30, and 365 days and examined for temporal trends by year. We estimated that with 7800 
Results
Study Cohort
Of 52 278 patients who met the eligibility criteria, were >65 years old, and were discharged alive after an ACS, we excluded 30 959 patients who within 7 days postindex discharge did not have a prescription for generic atorvastatin or Lipitor â , had both brand and generic atorvastatin dispensed, or died or were readmitted with ACS ( Figure 2 
Propensity-Matched Cohort
The mean age of the propensity-score-matched cohort was 76.9 years, 56.3% were male, and 87.6% had a myocardial infarction (MI) as the index ACS diagnosis (Table 1) . /atorvastatin dose was 47.7 mg and 47.2 mg/day, respectively. Mean 1-year medication possession ratio (adherence) was 88.4AE23.3 for brand and 88.4AE23.0 for generic atorvastatin. The most common generic atorvastatin product used in our study was Apoatorvastatin (77.2%) followed by Ran-atorvastatin (7.8%), Ratio-atorvastatin (4.6%), Co-atorvastatin (3.8%), and Novoatorvastatin (3.4%), with the remaining products each <2%. A comparison of the baseline characteristics of the treatment groups in the propensity-score-matched sample showed that the 2 groups were well balanced, with the standardized differences <0.1 (Table 1) . Baseline characteristics of the unmatched cohort are presented in Table S2 . 
Primary and Secondary Outcomes
At 1 year, the rate of death or recurrent ACS hospitalization in the propensity-score-matched sample was 17.7% among those prescribed generic atorvastatin and 17.7% for Lipitor â (HR, 1.00; 95% CI, 0.93-1.08; P=0.94; Table 2; Figure 3 ). There were also no differences in the 30-day rates of death or recurrent ACS between generic atorvastatin (3.7%) and Lipitor â (4.2%) (HR, 0.89; 95% CI, 0.76-1.04; P=0.16). No significant differences in rates of heart failure or stroke between treatment groups were observed at 30 days or 1 year (Table 2 ; Figure S1 ). No differences were found in the primary outcome between the 9 different generic atorvastatin products ( Figure 4) . As secondary outcomes, we also examined serious statin adverse events and found low 1-year rates for newly diagnosed diabetes (2.0% vs 1.9%; P=0.37) and rhabdomyolysis (P=0.39) in patients receiving generic atorvastatin and Lipitor â , respectively, with no difference between groups at 30 days or 1 year.
Sensitivity analysis using the exposure of generic atorvastatin or Lipitor â as a time-varying covariate in the overall cohort also found similar results for primary and secondary outcomes (Table S3) 
Subgroup Analyses
Prespecified subgroup analyses by age, sex, diabetes, atorvastatin dose, or admission diagnosis also found consistent results for the primary and secondary outcomes (Tables 3 and  4 Our study capitalized on a natural experiment within a large universal health system that was undergoing a mandatory policy change from Lipitor â to generic atorvastatin. We used this population-wide intervention to compare drug effectiveness in a high-risk ACS population who were prescribed an atorvastatin product within 7 days postdischarge. Lipitor â was automatically substituted to generic atorvastatin, as dictated by policy for the entire population. This policy mandate minimizes the chance of selection bias Comparability between groups in our large cohort was also strengthened by use of a propensity-matched cohort that was well balanced for baseline prognostic characteristics. Additional strengths include the discrete intervention, patientimportant clinical endpoints, and long-term follow-up. We conducted 2 sensitivity analyses, 1 that examined mortality in our cohort over the study period and 1 that restricted our analysis to 1-year pre-and postpolicy change to address potential secular trends in mortality over time and found no difference between groups, further strengthening our findings. Our findings are important because bioequivalence studies are not designed to test clinical efficacy or effectiveness, given their samples sizes of typically <50 patients, single-dose administration, investigation of drug absorption properties rather than clinical outcomes, and use of healthy volunteers. 5, 8, 9, 26 Meta-analyses of studies comparing brand-name and generic cardiovascular medications have found no difference between statins for lipid-level endpoints. 16 Direct comparison of clinical outcomes with brand and generic statins is limited to 1 study with simvastatin that found no difference in cardiovascular outcomes. [16] [17] [18] [19] [20] [27] [28] [29] As such, our study is the first to compare the effectiveness of clinical outcomes between generic atorvastatin and Lipitor â .
Quality control in generic manufacturing facilities has recently been questioned as drug recall notices have risen. 30, 31 Generic drug recalls, continued expansion of, and limited regulatory oversight for, overseas generic drug manufacturing facilities have raised public concern about the perceived safety and effectiveness of generic products. Reassuringly, we found no outcome differences between the 9 generic products, including some of the most common generic atorvastatin products used worldwide, Apo-atorvastatin and Ran-atorvastatin. [30] [31] [32] [33] A robust generic drug industry, producing effective therapies, coupled with a sufficient number of manufacturers to induce competitive pricing, is essential to support a sustainable health care system. 34, 35 We previously projected that the introduction of generic atorvastatin in the United States would reduce expenditures by $4.5 billion in 2014, a 77% savings. 36 Comparable savings were found for Ontario's public prescription benefit program, where total atorvastatin costs declined by 74% after the mandatory generic atorvastatin policy was instituted. 4 High drug costs are also an essential consideration in selecting drug therapy given that they may pose a barrier to medication adherence. 37 , 38 Gagne recently found that
Medicare patients initiating a generic statin (lovastatin, pravastatin, or simvastatin) were more likely to adhere, which may have translated into improved clinical outcomes. 39 Our study, demonstrating the effectiveness of generic atorvastatin versus Lipitor â , may reassure patients and clinicians about these generic products, potentially improving medication adherence, and may also support policy makers in their promotion of generic substitution policies.
Limitations
Our study has some limitations. We were able to create a well-balanced cohort through the use of propensity score methods. However, some risk factors (eg, smoking, physical activity) were not available. It is unlikely these factors were imbalanced enough in our cohort to impact our results. Because most in the brand group were from 2008 to 2010, and in the generic group from 2010 to 2012, there is possible confounding attributed to a temporal improvement in outcomes. In our propensity-matched cohort, baseline patient characteristics, medications within 7 days of index ACS discharge, and interventional cardiovascular procedures occurring during the ACS hospitalization were well balanced between groups, reducing the likelihood of confounding. In addition, our sensitivity analysis restricted to 1 year pre-and postpolicy change found similar results. Furthermore, analysis of mortality rates indicated no significant changes during our study's 4-year time frame. Our study is limited to an older cohort of patients ≥65 years. Smaller between-group differences are likely in younger patients. Although we found no significant difference in severe side effects, such as rhabdomyolysis and diabetes between the generic atorvastatin and Lipitor â groups, we were unable to evaluate common side effects, such as myalgias and gastrointestinal symptoms associated with statins given that they are not captured adequately in our data sources. We also do not have data on race/ ethnicity. Our study did not evaluate the impact of generic versus brand drug copay because the generic copay does not differ in Ontario.
In conclusion, our large, population-based study found that there is no difference in major adverse cardiovascular outcomes at 1 year in older ACS patients prescribed generic atorvastatin products after hospitalization compared with those prescribed Lipitor â . Our findings support the use of generic atorvastatin in ACS, which could lead to substantial cost saving without diminishing population clinical effectiveness. 
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